Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Recombinant butyrylcholinesterase (rBuChE) is a plant-produced enzyme being developed by AntoXa (a subsidiary of PlantForm Corporation) in collaboration with Defence Research & Development Canada (DRDC). It functions as a bioscavenger designed to protect against exposure to organophosphate nerve agents, such as sarin and soman. By binding to and neutralizing these toxic agents in the bloodstream before they can reach and inhibit endogenous acetylcholinesterase at the neuromuscular junction and in the central nervous system, rBuChE acts as a prophylactic or post-exposure treatment. The product is manufactured using a proprietary plant-based expression system (VivoExpress), which allows for rapid, scalable production of complex proteins.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on recombinant butyrylcholinesterase.